Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 277

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 277
---
 value on a recurring basis were presented on the Company’s statement of financial position as of October 31, 2023, as follows:

|                                |     | Fair                     
 Value Measurements Using |            Quoted 
            prices 
 in active markets 
     for identical 
       instruments 
         (Level 1) |     |   | Significant 
 other       
 observable  
 inputs      
 (Level 2)   |     |   |  Significant 
 unobservable 
       inputs 
    (Level 3) |     |   |     Balance 
 October 31, 
        2023 |
|:-------------------------------|:----|:-------------------------|------------------:|:----|:--|:------------|:----|:--|-------------:|:----|:--|------------:|
| Short-term investment          |     | $                        |            86,112 |     | $ | –           |     | $ |            – |     | $ |      86,112 |
| Derivative warrant liabilities |     |                          |                 – |     |   | –           |     |   |    4,310,379 |     |   |   4,310,379 |

The fair value of other assets and liabilities, which include cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments.

| b. | Credit Risk |

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure.

| c. | Foreign Exchange Rate Risk |

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in New Israeli Shekel and CAD. The Company has not entered into foreign exchange rate contracts to mitigate this risk.

F-32 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 12. | Financial                                   
 Instruments and Risk Management (continued) |

| c. | Foreign Exchange Rate Risk 
 (continued)                |

The